{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:50:05Z","timestamp":1792522205549,"version":"4.5.0"},"reference-count":157,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Science and Technology Plan of Jiangxi Provincial Health Commission","award":["202210918"],"award-info":[{"award-number":["202210918"]}]},{"name":"Science and Technology Plan of Jiangxi Provincial Health Commission","award":["GZ2022ZSF231"],"award-info":[{"award-number":["GZ2022ZSF231"]}]},{"name":"Guiding Science and Technology Programme of Ganzhou city","award":["202210918"],"award-info":[{"award-number":["202210918"]}]},{"name":"Guiding Science and Technology Programme of Ganzhou city","award":["GZ2022ZSF231"],"award-info":[{"award-number":["GZ2022ZSF231"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The survival rate for pediatric cancers has remarkably improved in recent years. Conventional chemotherapy plays a crucial role in treating pediatric cancers, especially in low- and middle-income countries where access to advanced treatments may be limited. The Food and Drug Administration (FDA) approved chemotherapy drugs that can be used in children have expanded, but patients still face numerous side effects from the treatment. In addition, multidrug resistance (MDR) continues to pose a major challenge in improving the survival rates for a significant number of patients. This review focuses on the severe side effects of pediatric chemotherapy, including doxorubicin-induced cardiotoxicity (DIC) and vincristine-induced peripheral neuropathy (VIPN). We also delve into the mechanisms of MDR in chemotherapy to the improve survival and reduce the toxicity of treatment. Additionally, the review focuses on various drug transporters found in common types of pediatric tumors, which could offer different therapeutic options.<\/jats:p>","DOI":"10.3390\/cancers15071963","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T02:18:27Z","timestamp":1679883507000},"page":"1963","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["The Battlefield of Chemotherapy in Pediatric Cancers"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6963-3293","authenticated-orcid":false,"given":"Letao","family":"Bo","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John\u2019s University, Queens, NY 11439, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyou","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John\u2019s University, Queens, NY 11439, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John\u2019s University, Queens, NY 11439, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John N. D.","family":"Wurpel","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John\u2019s University, Queens, NY 11439, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoufang","family":"Huang","sequence":"additional","affiliation":[{"name":"Ganzhou Key Laboratory of Hematology, Department of Hematology, The First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-097X","authenticated-orcid":false,"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John\u2019s University, Queens, NY 11439, USA"},{"name":"Institute for Biotechnology, St. John\u2019s University, Queens, NY 11439, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3322\/caac.21219","article-title":"Childhood and adolescent cancer statistics, 2014","volume":"64","author":"Ward","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5783","DOI":"10.1158\/0008-5472.CAN-21-1191","article-title":"Recent Advances in Pediatric Cancer Research","volume":"81","author":"McEachron","year":"2021","journal-title":"Cancer Res."},{"key":"ref_3","first-page":"428","article-title":"Dodging the bullet: Therapeutic resistance mechanisms in pediatric cancers","volume":"2","author":"Shah","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","unstructured":"GBD 2017 Childhood Cancer Collaborators (2019). The global burden of childhood and adolescent cancer in 2017: An analysis of the Global Burden of Disease Study 2017. Lancet Oncol., 20, 1211\u20131225."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.2014.60.6376","article-title":"Toward the Cure of All Children with Cancer Through Collaborative Efforts: Pediatric Oncology as a Global Challenge","volume":"33","author":"Friedrich","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41591-022-01738-x","article-title":"Priorities for cancer research in low- and middle-income countries: A global perspective","volume":"28","author":"Pramesh","year":"2022","journal-title":"Nat. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/S1470-2045(17)30727-1","article-title":"Tackling cancer burden in low-income and middle-income countries: Morocco as an exemplar","volume":"19","author":"Selmouni","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.annonc.2022.01.003","article-title":"Improving access to immunotherapy in low- and middle-income countries","volume":"33","author":"Patel","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/bjh.15785","article-title":"Optimizing outcomes for children with non-Hodgkin lymphoma in low- and middle-income countries by early correct diagnosis, reducing toxic death and preventing abandonment","volume":"185","author":"Chantada","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100789","DOI":"10.1016\/j.drup.2021.100789","article-title":"Molecular Modeling Strategies of Cancer Multidrug Resistance","volume":"59","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10555-019-09836-y","article-title":"Compare and contrast: Pediatric cancer versus adult malignancies","volume":"38","author":"Kattner","year":"2019","journal-title":"Cancer Metastasis Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1615\/CritRevOncog.2016016987","article-title":"Cell Death Induction in Cancer Therapy\u2014Past, Present, and Future","volume":"21","author":"Nonnenmacher","year":"2016","journal-title":"Crit. Rev. Oncog."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"150923","DOI":"10.1016\/j.soncn.2019.08.002","article-title":"Cancer and the Immune System: The History and Background of Immunotherapy","volume":"35","author":"Abbott","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMra1608986","article-title":"Recent Developments in Radiotherapy","volume":"377","author":"Citrin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41568-018-0003-x","article-title":"Too many targets, not enough patients: Rethinking neuroblastoma clinical trials","volume":"18","author":"Fletcher","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Malczewska, M., Kosmider, K., Bednarz, K., Ostapinska, K., Lejman, M., and Zawitkowska, J. (2022). Recent Advances in Treatment Options for Childhood Acute Lymphoblastic Leukemia. Cancers, 14.","DOI":"10.3390\/cancers14082021"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1016\/S1470-2045(21)00639-2","article-title":"Toxicity and efficacy of chronomodulated chemotherapy: A systematic review","volume":"23","author":"Printezi","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1586\/14737140.6.5.709","article-title":"Use of high-dose chemotherapy in front-line therapy of childhood malignant glioma","volume":"6","author":"Massimino","year":"2006","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_20","unstructured":"Mir, M. (2022). Combinational Therapy in Triple Negative Breast Cancer, Academic Press."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"108111","DOI":"10.1016\/j.pharmthera.2022.108111","article-title":"The immune modifying effects of chemotherapy and advances in chemo-immunotherapy","volume":"236","author":"Principe","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"17145","DOI":"10.1038\/s41598-020-73028-w","article-title":"Gap between pediatric and adult approvals of molecular targeted drugs","volume":"10","author":"Nishiwaki","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_23","first-page":"828","article-title":"Serious adverse events associated with chemotherapy in children with acute lymphoblastic leukemia","volume":"22","author":"Xu","year":"2020","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e27809","DOI":"10.1002\/pbc.27809","article-title":"Cancer drugs approved for use in children: Impact of legislative initiatives and future opportunities","volume":"66","author":"Barone","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00204-022-03418-8","article-title":"Proactive therapeutic drug monitoring of vincristine in pediatric and adult cancer patients: Current supporting evidence and future efforts","volume":"97","author":"Wu","year":"2022","journal-title":"Arch. Toxicol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/978-3-030-43032-0_15","article-title":"Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention","volume":"1257","author":"Bhagat","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/cphy.c180017","article-title":"Doxorubicin-Induced Cardiomyopathy in Children","volume":"9","author":"Mancilla","year":"2019","journal-title":"Compr. Physiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.critrevonc.2017.04.004","article-title":"Vincristine-induced peripheral neuropathy in children with cancer: A systematic review","volume":"114","author":"Kaspers","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"853","DOI":"10.4103\/0973-1482.139267","article-title":"An overview of doxorubicin formulations in cancer therapy","volume":"10","author":"Rivankar","year":"2014","journal-title":"J. Cancer Res. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e1637","DOI":"10.1002\/wnan.1637","article-title":"Nanomedicine and drug delivery systems in cancer and regenerative medicine","volume":"12","author":"Garbayo","year":"2020","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"105062","DOI":"10.1016\/j.phrs.2020.105062","article-title":"Cardiotoxicity of doxorubicin-based cancer treatment: What is the protective cognition that phytochemicals provide us?","volume":"160","author":"Liu","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"101394","DOI":"10.1016\/j.redox.2019.101394","article-title":"Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree?","volume":"29","author":"Kalyanaraman","year":"2020","journal-title":"Redox Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.stem.2021.08.006","article-title":"RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy","volume":"28","author":"Magdy","year":"2021","journal-title":"Cell Stem Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCULATIONAHA.121.055801","article-title":"Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity","volume":"145","author":"Magdy","year":"2022","journal-title":"Circulation"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41569-022-00757-y","article-title":"Circular RNA prevents doxorubicin-induced cardiotoxicity","volume":"19","author":"Lim","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1093\/eurheartj\/ehac337","article-title":"A circular RNA derived from the insulin receptor locus protects against doxorubicin-induced cardiotoxicity","volume":"43","author":"Lu","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1161\/CIRCRESAHA.119.316061","article-title":"The Tumor-Suppressive Human Circular RNA CircITCH Sponges miR-330-5p to Ameliorate Doxorubicin-Induced Cardiotoxicity Through Upregulating SIRT6, Survivin, and SERCA2a","volume":"127","author":"Han","year":"2020","journal-title":"Circ. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1161\/CIRCRESAHA.121.319104","article-title":"atg7-Based Autophagy Activation Reverses Doxorubicin-Induced Cardiotoxicity","volume":"129","author":"Wang","year":"2021","journal-title":"Circ. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"101747","DOI":"10.1016\/j.redox.2020.101747","article-title":"Meteorin-like protein attenuates doxorubicin-induced cardiotoxicity via activating cAMP\/PKA\/SIRT1 pathway","volume":"37","author":"Hu","year":"2020","journal-title":"Redox Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"102310","DOI":"10.1016\/j.redox.2022.102310","article-title":"Cardiac SIRT1 ameliorates doxorubicin-induced cardiotoxicity by targeting sestrin 2","volume":"52","author":"Wang","year":"2022","journal-title":"Redox Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2150394","DOI":"10.1155\/2019\/2150394","article-title":"Berberine Ameliorates Doxorubicin-Induced Cardiotoxicity via a SIRT1\/p66Shc-Mediated Pathway","volume":"2019","author":"Wu","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ymthe.2021.07.004","article-title":"ADAR2 increases in exercised heart and protects against myocardial infarction and doxorubicin-induced cardiotoxicity","volume":"30","author":"Wu","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"106186","DOI":"10.1016\/j.phrs.2022.106186","article-title":"Elabela ameliorates doxorubicin-induced cardiotoxicity by promoting autophagic flux through TFEB pathway","volume":"178","author":"Chen","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ejhf.1439","article-title":"The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity","volume":"21","author":"Russo","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.trsl.2022.05.001","article-title":"Gasdermin D mediates doxorubicin-induced cardiomyocyte pyroptosis and cardiotoxicity via directly binding to doxorubicin and changes in mitochondrial damage","volume":"248","author":"Ye","year":"2022","journal-title":"Transl. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1038\/s12276-020-00541-3","article-title":"Melatonin prevents doxorubicin-induced cardiotoxicity through suppression of AMPKalpha2-dependent mitochondrial damage","volume":"52","author":"Yang","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/cvr\/cvz163","article-title":"Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose-dependent manner: Implications for inotropy","volume":"116","author":"Efentakis","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ding, M., Shi, R., Fu, F., Li, M., De, D., Du, Y., and Li, Z. (J. Adv. Res., 2022). Paeonol protects against doxorubicin-induced cardiotoxicity by promoting Mfn2-mediated mitochondrial fusion through activating the PKCepsilon-Stat3 pathway, J. Adv. Res., in press.","DOI":"10.1016\/j.jare.2022.07.002"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"105642","DOI":"10.1016\/j.phrs.2021.105642","article-title":"SNX17 protects the heart from doxorubicin-induced cardiotoxicity by modulating LMOD2 degradation","volume":"169","author":"Zhang","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"102120","DOI":"10.1016\/j.redox.2021.102120","article-title":"Irisin ameliorates doxorubicin-induced cardiac perivascular fibrosis through inhibiting endothelial-to-mesenchymal transition by regulating ROS accumulation and autophagy disorder in endothelial cells","volume":"46","author":"Pan","year":"2021","journal-title":"Redox Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.apsb.2020.10.017","article-title":"Isorhapontigenin protects against doxorubicin-induced cardiotoxicity via increasing YAP1 expression","volume":"11","author":"Wang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"104846","DOI":"10.1016\/j.phrs.2020.104846","article-title":"Mitophagy inhibitor liensinine suppresses doxorubicin-induced cardiotoxicity through inhibition of Drp1-mediated maladaptive mitochondrial fission","volume":"157","author":"Liang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1016\/j.bmcl.2018.06.044","article-title":"Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead","volume":"28","author":"Martino","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12935-020-01251-6","article-title":"N-alkylisatin-based microtubule destabilizers bind to the colchicine site on tubulin and retain efficacy in drug resistant acute lymphoblastic leukemia cell lines with less in vitro neurotoxicity","volume":"20","author":"Keenan","year":"2020","journal-title":"Cancer Cell Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.joms.2005.12.022","article-title":"Bilateral recurrent laryngeal nerve palsy resulting from treatment with vincristine","volume":"64","author":"Harris","year":"2006","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/08880018.2019.1677832","article-title":"Vincristine-induced peripheral neurotoxicity: A prospective cohort","volume":"37","author":"Nama","year":"2020","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejca.2021.09.014","article-title":"Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients","volume":"164","author":"Barnett","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Uittenboogaard, A., Neutel, C.L.G., Ket, J.C.F., Njuguna, F., Huitema, A.D.R., Kaspers, G.J.L., and van de Velde, M.E. (2022). Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy in Children with Cancer: A Systematic Review and Meta-Analysis. Cancers, 14.","DOI":"10.3390\/cancers14030612"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Triarico, S., Romano, A., Attina, G., Capozza, M.A., Maurizi, P., Mastrangelo, S., and Ruggiero, A. (2021). Vincristine-Induced Peripheral Neuropathy (VIPN) in Pediatric Tumors: Mechanisms, Risk Factors, Strategies of Prevention and Treatment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084112"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/1043454218762705","article-title":"Assessment Tools for Peripheral Neuropathy in Pediatric Oncology: A Systematic Review from the Children\u2019s Oncology Group","volume":"35","author":"Smolik","year":"2018","journal-title":"J. Pediatr. Oncol. Nurs."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"710163","DOI":"10.3389\/fonc.2021.710163","article-title":"Long-Term Effects of Pediatric Acute Lymphoblastic Leukemia Chemotherapy: Can Recent Findings Inform Old Strategies?","volume":"11","author":"AlAhmad","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"100420","DOI":"10.1016\/j.ctarc.2021.100420","article-title":"Characteristics and patterns of pediatric chemotherapy-induced peripheral neuropathy: A systematic review","volume":"28","author":"Smith","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00280-019-03884-5","article-title":"Aspects of vincristine-induced neuropathy in hematologic malignancies: A systematic review","volume":"84","author":"Madsen","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e26471","DOI":"10.1002\/pbc.26471","article-title":"Vincristine-induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia","volume":"64","author":"Tay","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.12669\/pjms.37.5.4169","article-title":"Vincristine induced neurotoxicity in children who underwent chemotherapy for acute lymphoblastic leukemia and Wilm\u2019s tumor","volume":"37","author":"Adil","year":"2021","journal-title":"Pak. J. Med. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neuro.2020.10.004","article-title":"Vincristine-induced peripheral neuropathy: A mini-review","volume":"81","author":"Li","year":"2020","journal-title":"Neurotoxicology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"771487","DOI":"10.3389\/fphar.2021.771487","article-title":"Vincristine-Induced Peripheral Neuropathy in Childhood Acute Lymphoblastic Leukemia: Genetic Variation as a Potential Risk Factor","volume":"12","author":"Yang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/17425255.2021.1855141","article-title":"Genetic factors influencing the development of vincristine-induced neurotoxicity","volume":"17","author":"Pozzi","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/cpt.506","article-title":"An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults with Acute Lymphoblastic Leukemia","volume":"101","author":"Stock","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/pbc.22845","article-title":"Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia","volume":"56","author":"Egbelakin","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/FPC.0000000000000345","article-title":"Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: A single institution study","volume":"28","author":"Zgheib","year":"2018","journal-title":"Pharmacogenet. Genom."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2217\/pgs-2016-0001","article-title":"Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia","volume":"17","author":"Astigarraga","year":"2016","journal-title":"Pharmacogenomics"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s13311-019-00784-7","article-title":"Levo-corydalmine Attenuates Vincristine-Induced Neuropathic Pain in Mice by Upregulating the Nrf2\/HO-1\/CO Pathway to Inhibit Connexin 43 Expression","volume":"17","author":"Zhou","year":"2020","journal-title":"Neurotherapeutics"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.neuropharm.2018.03.004","article-title":"Levo-corydalmine alleviates vincristine-induced neuropathic pain in mice by inhibiting an NF-kappa B-dependent CXCL1\/CXCR2 signaling pathway","volume":"135","author":"Zhou","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"110003","DOI":"10.1016\/j.biopha.2020.110003","article-title":"Mitoquinone alleviates vincristine-induced neuropathic pain through inhibiting oxidative stress and apoptosis via the improvement of mitochondrial dysfunction","volume":"125","author":"Chen","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"107060","DOI":"10.1016\/j.intimp.2020.107060","article-title":"Puerarin alleviates vincristine-induced neuropathic pain and neuroinflammation via inhibition of nuclear factor-kappaB and activation of the TGF-beta\/Smad pathway in rats","volume":"89","author":"Xie","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1038\/s41401-022-00904-8","article-title":"NGF monoclonal antibody DS002 alleviates chemotherapy-induced peripheral neuropathy in rats","volume":"43","author":"Liang","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3389\/fnins.2019.00653","article-title":"Minocycline Prevents the Development of Mechanical Allodynia in Mouse Models of Vincristine-Induced Peripheral Neuropathy","volume":"13","author":"Starobova","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1021\/acschemneuro.9b00206","article-title":"Bergapten Ameliorates Vincristine-Induced Peripheral Neuropathy by Inhibition of Inflammatory Cytokines and NFkappaB Signaling","volume":"10","author":"Singh","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"Teng","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","article-title":"Ferroptosis in cancer therapy: A novel approach to reversing drug resistance","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.phrs.2017.07.023","article-title":"MDR in cancer: Addressing the underlying cellular alterations with the use of nanocarriers","volume":"126","author":"Singh","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.canlet.2014.03.013","article-title":"Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches","volume":"347","author":"Wu","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrd4626","article-title":"SLC transporters as therapeutic targets: Emerging opportunities","volume":"14","author":"Lin","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41589-020-0483-3","article-title":"A widespread role for SLC transmembrane transporters in resistance to cytotoxic drugs","volume":"16","author":"Girardi","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/abbs\/gmab076","article-title":"Prognostic SLC family genes promote cell proliferation, migration, and invasion in hepatocellular carcinoma","volume":"53","author":"Fang","year":"2021","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2174\/1381612825666190329141003","article-title":"Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt from the Genetic Variants of Drug Transporters","volume":"25","author":"Hu","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrc2789","article-title":"ABC transporters in cancer: More than just drug efflux pumps","volume":"10","author":"Fletcher","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"253","DOI":"10.20892\/j.issn.2095-3941.2019.0284","article-title":"ABC transporters and the hallmarks of cancer: Roles in cancer aggressiveness beyond multidrug resistance","volume":"17","author":"Muriithi","year":"2020","journal-title":"Cancer Biol. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bbagen.2018.09.019","article-title":"ABC transporters as cancer drivers: Potential functions in cancer development","volume":"1863","author":"Domenichini","year":"2019","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.semcancer.2019.10.004","article-title":"The ABC subfamily A transporters: Multifaceted players with incipient potentialities in cancer","volume":"60","author":"Pasello","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4155\/fmc-2018-0403","article-title":"Gaseous signaling molecules and their application in resistant cancer treatment: From invisible to visible","volume":"11","author":"Cui","year":"2019","journal-title":"Future Med. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.semcancer.2019.08.006","article-title":"Role of ATP-binding cassette transporters in cancer initiation and progression","volume":"60","author":"Nobili","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s11033-021-06155-w","article-title":"ABC transporter superfamily. An updated overview, relevance in cancer multidrug resistance and perspectives with personalized medicine","volume":"48","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/jebm.12434","article-title":"ATP-binding cassette (ABC) transporters in cancer: A review of recent updates","volume":"14","author":"Wang","year":"2021","journal-title":"J. Evid. Based Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"110718","DOI":"10.1016\/j.biopha.2020.110718","article-title":"Effect of ABC transporter expression and mutational status on survival rates of cancer patients","volume":"131","author":"Kadioglu","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.bbamem.2017.10.028","article-title":"Comparison of mechanistic transport cycle models of ABC exporters","volume":"1860","author":"Szollosi","year":"2018","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1152\/physrev.00037.2005","article-title":"Human multidrug resistance ABCB and ABCG transporters: Participation in a chemoimmunity defense system","volume":"86","author":"Sarkadi","year":"2006","journal-title":"Physiol. Rev."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"26245","DOI":"10.1073\/pnas.2010264117","article-title":"Cryo-EM structures reveal distinct mechanisms of inhibition of the human multidrug transporter ABCB1","volume":"117","author":"Nosol","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szakacs","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/10915810600746023","article-title":"Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters","volume":"25","author":"Choudhuri","year":"2006","journal-title":"Int. J. Toxicol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"20640","DOI":"10.1038\/s41598-020-77140-9","article-title":"Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients","volume":"10","author":"Rajamani","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"615824","DOI":"10.3389\/fphar.2020.615824","article-title":"Elevated ABCB1 Expression Confers Acquired Resistance to Aurora Kinase Inhibitor GSK-1070916 in Cancer Cells","volume":"11","author":"Wu","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Wang, J., Yang, D.H., Yang, Y., Wang, J.Q., Cai, C.Y., Lei, Z.N., Teng, Q.X., Wu, Z.X., Zhao, L., and Chen, Z.S. (2020). Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041387"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/med.21750","article-title":"Molecular targeting therapies for neuroblastoma: Progress and challenges","volume":"41","author":"Zafar","year":"2021","journal-title":"Med. Res. Rev."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/jnci\/81.18.1401","article-title":"Correlation of MDR1 gene expression with chemotherapy in neuroblastoma","volume":"81","author":"Bourhis","year":"1989","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11010-006-9404-3","article-title":"MDR1 hypermethylation contributes to the progression of neuroblastoma","volume":"301","author":"Qiu","year":"2007","journal-title":"Mol. Cell. Biochem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jpedsurg.2008.10.088","article-title":"Increased expression of multidrug resistance-associated genes after chemotherapy in pediatric solid malignancies","volume":"44","author":"Oue","year":"2009","journal-title":"J. Pediatr. Surg."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"100743","DOI":"10.1016\/j.drup.2021.100743","article-title":"Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance","volume":"54","author":"Wang","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev-pharmtox-011613-135959","article-title":"Targeting multidrug resistance protein 1 (MRP1, ABCC1): Past, present, and future","volume":"54","author":"Cole","year":"2014","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.2174\/0929867324666171012105143","article-title":"ATP-binding Cassette Exporters: Structure and Mechanism with a Focus on P-glycoprotein and MRP1","volume":"26","author":"Arana","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"308","DOI":"10.2174\/1567205010666131212110948","article-title":"Drug Transporters and Multiple Drug Resistance in Pediatric Solid Tumors","volume":"17","author":"Fruci","year":"2016","journal-title":"Curr. Drug Metab."},{"key":"ref_115","first-page":"184","article-title":"Pattern of ABCC Transporter Gene Expression in Pediatric Patients with Relapsed Acute Lymphoblastic Leukemia","volume":"8","author":"Mehrvar","year":"2019","journal-title":"Rep. Biochem. Mol. Biol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/jnci\/djr256","article-title":"ABCC multidrug transporters in childhood neuroblastoma: Clinical and biological effects independent of cytotoxic drug efflux","volume":"103","author":"Henderson","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/med.21428","article-title":"ABCG2\/BCRP: Specific and Nonspecific Modulators","volume":"37","author":"Stark","year":"2017","journal-title":"Med. Res. Rev."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"101579","DOI":"10.1016\/j.pdpdt.2019.10.014","article-title":"The role of ABCG2 in modulating responses to anti-cancer photodynamic therapy","volume":"29","author":"Khot","year":"2020","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fphar.2019.00208","article-title":"Inhibitors of Human ABCG2: From Technical Background to Recent Updates with Clinical Implications","volume":"10","author":"Toyoda","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1016\/j.bmc.2008.02.050","article-title":"Synthesis and structure-activity relationship studies on tryprostatin A, an inhibitor of breast cancer resistance protein","volume":"16","author":"Jain","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"114346","DOI":"10.1016\/j.ejmech.2022.114346","article-title":"Targeting breast cancer resistance protein (BCRP\/ABCG2): Functional inhibitors and expression modulators","volume":"237","author":"Zattoni","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"15665","DOI":"10.1073\/pnas.95.26.15665","article-title":"A multidrug resistance transporter from human MCF-7 breast cancer cells","volume":"95","author":"Doyle","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1365-2141.2002.03550.x","article-title":"Expression of the BCRP gene (ABCG2\/MXR\/ABCP) in childhood acute lymphoblastic leukaemia","volume":"118","author":"Sauerbrey","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/sj.leu.2402496","article-title":"Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)","volume":"16","author":"Wiemer","year":"2002","journal-title":"Leukemia"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"14228","DOI":"10.1073\/pnas.0400067101","article-title":"A distinct \u201cside population\u201d of cells with high drug efflux capacity in human tumor cells","volume":"101","author":"Foster","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2174\/138161282005140214165212","article-title":"ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development","volume":"20","author":"Choi","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/bjc.2016.203","article-title":"ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells","volume":"115","author":"Vaidyanathan","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1349-7006.2008.00744.x","article-title":"Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients","volume":"99","author":"Lal","year":"2008","journal-title":"Cancer Sci."},{"key":"ref_129","first-page":"141","article-title":"Drug resistance and combating drug resistance in cancer","volume":"2","author":"Wang","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3390\/cancers12010195","article-title":"Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs","volume":"12","author":"Wu","year":"2020","journal-title":"Cancers"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3389\/fonc.2018.00173","article-title":"Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance","volume":"8","author":"Ahmed","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_132","first-page":"4237","article-title":"The mouse Bcrp1\/Mxr\/Abcp gene: Amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin","volume":"59","author":"Allen","year":"1999","journal-title":"Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.7150\/thno.57828","article-title":"Recent progress in nanomedicine for enhanced cancer chemotherapy","volume":"11","author":"Wei","year":"2021","journal-title":"Theranostics"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/s41598-018-19325-x","article-title":"Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells","volume":"8","author":"Nanayakkara","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/mco2.106","article-title":"Overcoming multidrug resistance by knockout of ABCB1 gene using CRISPR\/Cas9 system in SW620\/Ad300 colorectal cancer cells","volume":"2","author":"Lei","year":"2021","journal-title":"MedComm"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Yee Kuen, C., and Masarudin, M.J. (2022). Chitosan Nanoparticle-Based System: A New Insight into the Promising Controlled Release System for Lung Cancer Treatment. Molecules, 27.","DOI":"10.3390\/molecules27020473"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/ptr.6694","article-title":"Application of curcumin and its derivatives in tumor multidrug resistance","volume":"34","author":"Xu","year":"2020","journal-title":"Phytother. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"688070","DOI":"10.3389\/fcell.2021.688070","article-title":"Surface PEGylated Cancer Cell Membrane-Coated Nanoparticles for Codelivery of Curcumin and Doxorubicin for the Treatment of Multidrug Resistant Esophageal Carcinoma","volume":"9","author":"Gao","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"100754","DOI":"10.1016\/j.drup.2021.100754","article-title":"Therapeutic strategies to overcome taxane resistance in cancer","volume":"55","author":"Das","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/138920107780487465","article-title":"Drug resistance in childhood acute myeloid leukemia","volume":"8","author":"Styczynski","year":"2007","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"105806","DOI":"10.1016\/j.phrs.2021.105806","article-title":"Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS","volume":"172","author":"Roskoski","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature25480","article-title":"The landscape of genomic alterations across childhood cancers","volume":"555","author":"Grobner","year":"2018","journal-title":"Nature"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Drozak, P., Brylinski, L., and Zawitkowska, J. (2022). A Comprehensive Overview of Recent Advances in Epigenetics in Pediatric Acute Lymphoblastic Leukemia. Cancers, 14.","DOI":"10.3390\/cancers14215384"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41591-019-0383-9","article-title":"Developmental origins and emerging therapeutic opportunities for childhood cancer","volume":"25","author":"Filbin","year":"2019","journal-title":"Nat. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.semcancer.2017.09.001","article-title":"Epigenetics in pediatric acute lymphoblastic leukemia","volume":"51","author":"Nordlund","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_146","first-page":"49","article-title":"Acute lymphoblastic leukemia in adolescents and young adults\u2014From genomics to the clinics","volume":"3","author":"Kenderian","year":"2013","journal-title":"Clin. Oncol. Adolesc. Young Adults"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Neaga, A., Jimbu, L., Mesaros, O., Bota, M., Lazar, D., Cainap, S., Blag, C., and Zdrenghea, M. (2021). Why Do Children with Acute Lymphoblastic Leukemia Fare Better Than Adults?. Cancers, 13.","DOI":"10.3390\/cancers13153886"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/10428190290006071","article-title":"In vitro drug resistance profiles of adult acute lymphoblastic leukemia: Possible explanation for difference in outcome to similar therapeutic regimens","volume":"43","author":"Styczynski","year":"2002","journal-title":"Leuk. Lymphoma"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/bloodadvances.2018028993","article-title":"Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia","volume":"3","author":"Alcantara","year":"2019","journal-title":"Blood Adv."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020010081","article-title":"PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL","volume":"138","author":"Andrieu","year":"2021","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"106612","DOI":"10.1016\/j.leukres.2021.106612","article-title":"Adverse prognostic impact of complex karyotype (>\/=3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)","volume":"109","author":"Genesca","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"6604","DOI":"10.1038\/ncomms7604","article-title":"Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia","volume":"6","author":"Ma","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3322\/caac.21731","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J. Clin"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Jeenia, F.T., Sojib, F.A., Rahman, M.S., Ara, T., Khan, R., and Tanin, M.J.U.J.M. Neuroprotective effect of vitamin B6 and vitamin B12 against vincristine-induced peripheral neuropathy: A randomized, double-blind, placebo controlled, multicenter trial. medRxiv, 2021.","DOI":"10.1101\/2021.05.18.21257296"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S1470-2045(18)30858-1","article-title":"Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium","volume":"20","author":"Clemens","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejca.2020.07.019","article-title":"Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study","volume":"138","author":"Langer","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2021.10.035","article-title":"The PanCareFollowUp Care Intervention: A European harmonised approach to person-centred guideline-based survivorship care after childhood, adolescent and young adult cancer","volume":"162","author":"Mulder","year":"2022","journal-title":"Eur. J. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/7\/1963\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:02:48Z","timestamp":1760122968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/7\/1963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":157,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["cancers15071963"],"URL":"https:\/\/doi.org\/10.3390\/cancers15071963","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,24]]}}}